Method for the assessment of the therapeutic dose appropriate acid 1 - (4 - [1 - (4 - Cyclohexyl - 3 - trifluoromethyl - benciloxiimino) ethyl] - 2 - ethyl - 3 - benzyl} - azetidin acid for Administering to a patient in need, which comprises the steps of: (i) to analyze whether or Not the patient has the genotype Poor metaboliser； and (ii) if the patient has no Poor metaboliser genotype,Manage acid 1 - (4 - [1 - (4 - Cyclohexyl - 3 - trifluoromethyl - benciloxiimino) ethyl] - 2 - Ethyl benzyl} - azetidin - 3 carboxylic acid or its Salts, Pharmaceutical acceptable from the point of view, the patient to standard Therapeutic dose； and (iii) if the patient has the shortcomings metaboliser Genotype You,(a) managing acid or 1 - (4 - [1 - (4 - Cyclohexyl - 3 - trifluoromethyl - benciloxiimino) ethyl] - 2 - Ethyl benzyl} - azetidin - 3 carboxylic acid or its Salt acceptable from the point of view of pharmaceuticalThe patient in a Therapeutic dose lower than the standard Therapeutic dose； or (b) manage acid 1 - (4 - [1 - (4 - Cyclohexyl - 3 - trifluoromethyl - benciloxiimino) ethyl] - 2 - Ethyl benzyl} - azetidin - 3 carboxylic acid or its Salt acceptable from the pharmacist's Point of view, The patient.Método para la evaluación de la dosis terapéutica apropiada de ácido 1-{4-[1-(4-ciclohexil-3-trifluorometil-benciloxiimino)-etil]-2-etil-bencil}-azetidin-3-carboxílico para administrar a un paciente que lo necesita, que comprende los pasos de: (i) analizar si el paciente tiene o no el genotipo metabolizador deficiente； y (ii) si el paciente no tiene el genotipo metabolizador deficiente, administrar ácido 1-{4-[1-(4-ciclohexil-3-trifluorometil-benciloxiimino)-etil]-2-etil-bencil}-azetidin-3-carboxílico, o una de sus sales aceptables desde el punto de vista farmacéutico, al paciente a la dosis terapéutica estándar； y (iii) si el paciente tiene el genotipo metabolizador deficiente, o bien (a) administrar ácido 1-{4-[1-(4-ciclohexil-3-trifluorometil-benciloxiimino)-etil]-2-etil-b
